ENTITY

Immunogen Inc (IMGN US)

Analysis

Health Care • United States

ImmunoGen, Inc. develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology together with its expertise in monoclonal antibodies and tumor biology. A TAP compound uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's purpose-developed cancer-killing agents specifically to tumor cells.

Refresh

Company Presentation • 02 Nov 2023 05:00

Corporate Presentation

Company Presentation • 20 Mar 2022 22:30

Investor Update

Company Presentation • 11 Jan 2023 07:45

JPMorgan Healthcare Conference

Company Presentation • 03 Nov 2022 18:48

Investor Presentation

No more presentations

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00